TEL AVIV, Israel, July 17, 2018 /PRNewswire/ -- Therapix Biosciences Ltd. (NASDAQ: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, announced today positive results in its pre-clinical studies evaluating THX-160, a novel pharmaceutical CB2 Receptor agonist for the treatment of pain. This innovative CB2 receptor agonist, which was found to be superior out of two candidates the Company had tested, was synthesized by Raphael Mechoulam, Ph.D., Professor of Medicinal Chemistry at the Hebrew University, and a member of the Therapix Scientific Advisory Board.
To date, prescription opioids are considered to be the most effective treatment for moderate-to-severe pain, but their abuse has been identified by the U.S. Food and Drug Administration (FDA) and the Centers for Disease Control (CDC) as a significant public health issue.
In the preclinical studies, THX-160 was well tolerated and did not cause any significant adverse clinical effects. In addition, efficacy studies demonstrated the analgesic superiority of THX-160 over control and were comparable to high-dose morphine analgesic effects and in some instances exerted greater potency. The efficacy and safety of THX-160 was shown for both acute and chronic pain.
"This encouraging data, along with prior published preclinical efficacy results for a CB2R agonist's involvement in pain relief, reinforce our belief that our lead drug candidate, THX-160, has a favorable safety and efficacy profile that could potentially address the unmet need for well-tolerated and safe oral pain therapies with improved patient quality of life," said Dr. Adi Zuloff-Shani, Chief Technology Officer at Therapix. "The novel cannabinoid we added to the Company's portfolio highlights Therapix's commitment to continue and develop our cannabinoid platform, and potentially translating into innovative new treatments."
"These compelling THX-160 results represent an important milestone towards the development of Therapix Biosciences pain related assets which will take an increasing part in the Company's technology portfolio," said Dr. Ascher Shmulewitz, Chairman and CEO. "Based on the results generated to date and its profile, we believe THX-160 has the potential to be a new treatment option for pain patients, and reduce the risks of opiate addiction."
About Therapix Biosciences:
Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of Senior Executives and Scientists. Our focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in the following drug development programs based on repurposing an FDA-approved cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain. Please visit our website for more information at www.therapixbio.com.
Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Because such statements deal with future events and are based on Therapix's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Therapix could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding the Company's plans with respect to its clinical trials and its intent to report material developments and information regarding such trials. In addition, historic results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Therapix Biosciences Ltd.'s Annual Report on Form 20-F filed with the Securities and Exchange Commission (SEC) on April 30, 2018 and in subsequent filings with the SEC. Except as otherwise required by law, Therapix disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.
SOURCE Therapix Biosciences Ltd.